We are thrilled to announce the grand opening of our Center for Clinical and Commercial Manufacturing of Advanced Therapies in the Philadelphia Navy Yard.
The 150,000 square foot biomanufacturing facility is designed for cell therapy products that utilize viral vectors such as chimeric antigen receptor T cell (CAR T cell) therapies. In addition, the facility will permit expansion of viral vector manufacturing to support gene therapy clinical and commercial programs and will permit large scale production in 2,000L single-use bioreactors. The new facility will supplement WuXi’s existing 20,000 square-foot cGMP cell therapy manufacturing facility, as well as a 50,000-square-foot facility for the commercial manufacturing of allogeneic and autologous cell-based therapeutics.
Advanced therapies like CAR T-cells and gene therapy vectors offer significant new therapeutic options for cancer patients and those suffering from crippling genetic diseases. We are pleased to be on the forefront of this field, providing our partners with cutting-edge cGMP manufacturing capabilities and capacities.